NCT01111981Unknown4 期
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in the Treatment of Central Centrifugal Cicatricial Alopecia
Callender Center for Clinical Research2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2009年10月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- Improvement of pruritis, tenderness, and pain
研究概览
简要总结
The purpose of this study is to ascertain the safety and efficacy of
Clobetasol Propionate 0.05% E Foam in the treatment of Central Centrifugal
Cicatricial Alopecia.
详细描述
Central Centrifugal Cicatricial Alopecia (CCCA) is an inflammation-induced
hair loss starting in the central scalp and progressing centrifugally. The
cause of CCCA is unknown. Early diagnosis and treatment is essential to stop
or slow the progression of scarring and permanent hair loss. Once scarring
occurs, the hair follicles are obliterated and the hair cannot regrow. Thus,
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with CCCA, treated or untreated
- •Score 0 - 1 on Scale/Questionnaire
- •18 years of age or older
- •Women of African descent
排除标准
- •Score > 1 on Scale/Questionnaire
- •Alopecias other than CCCA, including alopecia arreata, lichen planopilaris, trichotillomania, and traction alopecia
- •History of hair transplantation
- •Children less than 18 years of age
- •Women of non-African descent
- •Pregnancy or breastfeeding. Women of childbearing age must use reliable forms of contraception (e.g., abstinence, oral contraceptives, or spermicide and condoms)
- •Anti-dandruff shampoo within 30 days
- •Anti-inflammatory medications such as antibiotics (doxycycline, minocycline, rifampin, etc.), steroids (oral prednisone, topical corticosteroids,etc.), NSAIDs (ibuprofen, aspirin, etc.)
结局指标
主要结局
Improvement of pruritis, tenderness, and pain
时间窗: 4 months
次要结局
- Absence of inflammation on biopsy(4 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic DermatitisScalp Seborrheic DermatitisNCT00862654Galderma R&D326
已完成
4 期
Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle FoamPsoriasisNCT00842153Stiefel, a GSK Company58
已完成
4 期
A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) FoamPsoriasisNCT00436540Galderma R&D78
已完成
4 期
Study to Evaluate Safety, Efficacy and Tolerability of Clobetasol Propionate for Chronic Hand DermatitisHand DermatosisNCT00828464Stiefel, a GSK Company30
已完成
4 期
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the ScalpScalp PsoriasisNCT00881868Galderma R&D81